Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,705,337

« Back to Dashboard

Details for Patent: 5,705,337

Title: Systematic evolution of ligands by exponential enrichment: chemi-SELEX
Abstract:This application provides methods for identifying nucleic acid ligands capable of covalently interacting with targets of interest. The nucleic acids can be associated with various functional units. The method also allows for the identification of nucleic acids that have facilitating activities as measured by their ability to facilitate formation of a covalent bond between the nucleic acid, including its associated functional unit, and its target.
Inventor(s): Gold; Larry (Boulder, CO), Eaton; Bruce (Boulder, CO), Smith; Drew (Boulder, CO), Wecker; Matthew (Boulder, CO), Jensen; Kirk (Boulder, CO)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Mar 08, 1995
Application Number:08/400,440
Claims:1. A method for identifying nucleic acid ligands that bind covalently with a target molecule from a candidate mixture of nucleic acids wherein each nucleic acid in said candidate mixture comprises a chemically reactive functional unit, said method comprising:

a) preparing a candidate mixture of said nucleic acids;

b) contacting said candidate mixture with said target molecule, wherein nucleic acids which bind covalently with said target molecule form nucleic acid-target molecule complexes;

c) partitioning the nucleic acid-target molecule complexes from the remainder of the candidate mixture, whereby nucleic acid ligands that bind covalently with the target molecule are identified.

2. The method of claim 1 wherein after step c), the nucleic acid is amplified and steps b) through c) repeated until a mixture of nucleic acids enriched in sequences that bind covalently with the target molecule is obtained.

3. The method of claim 1 wherein said chemically reactive functional unit is selected from the group consisting of photoreactive groups, active site directed compounds and peptides.

4. The method of claim 1 wherein the target is modified to include a chemical moiety that reacts with the chemically reactive functional unit of the nucleic acid.

5. The method of claim 1 wherein said nucleic acid comprises a fixed region and a randomized region.

6. The method of claim 5 wherein said chemically reactive functional unit is attached to an oligonucleotide hybridized to said fixed region.

7. The method of claim 1 wherein said target is selected from the group consisting of bradykinin, elastase, and HIV-1 Rev.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.